Monte Rosa Therapeutics (GLUE) EBIT Margin (2024 - 2026)
Monte Rosa Therapeutics' (GLUE) quarterly EBIT Margin came in at 1163.58% in Q1 2026, down 121543.0% year-on-year from N/an in Q1 2025, and up 34.91% quarter-over-quarter from 1787.67% in Q4 2025.
Monte Rosa Therapeutics (GLUE) EBIT Margin (2024 - 2026) Analysis & Trends
Monte Rosa Therapeutics' EBIT Margin history runs 3 years deep, the most recent figure standing at 1163.58% for Q1 2026.
- On a quarterly basis, EBIT Margin fell 121543.0% year-over-year to 1163.58% in Q1 2026; TTM through Mar 2026 was 3448.33%, a 344699.0% decrease from a year earlier, with the FY2025 full-year figure at 43.83%, up 6343.0% from the prior year.
- EBIT Margin grew to 1163.58% in Q1 2026 per GLUE's latest filing, from 1787.67% in the prior quarter.
- Across five years, EBIT Margin topped out at 51.85% in Q1 2025 and bottomed at 3284.49% in Q1 2024.
- The 3-year median for EBIT Margin is 287.84% (2024), against an average of 797.62%.
- Biggest YoY gain for EBIT Margin was 333634 bps in 2025; the steepest drop was 180911 bps in 2025.
- Year by year, EBIT Margin stood at 21.44% in 2024, then slumped by 8437 bps to 1787.67% in 2025, then surged by 35 bps to 1163.58% in 2026.
- Per Business Quant, the three latest GLUE EBIT Margin figures stand at 1163.58% (Q1 2026), 1787.67% (Q4 2025), and 21.98% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Monte Rosa Therapeutics | 2.30 Bn | 1.62 Bn | - | -1,163.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,163.58% |
| Dec 31, 2025 | -1,787.67% |
| Sep 30, 2025 | -21.98% |
| Jun 30, 2025 | -11.09% |
| Mar 31, 2025 | 51.85% |
| Dec 31, 2024 | 21.44% |
| Sep 30, 2024 | -287.84% |
| Jun 30, 2024 | -695.25% |
| Mar 31, 2024 | -3,284.49% |